Last reviewed · How we verify
Fluticasone Propionate (FP)
Fluticasone propionate is a corticosteroid that binds to glucocorticoid receptors in the cytoplasm, translocates to the nucleus, and suppresses inflammatory gene transcription to reduce airway inflammation.
Fluticasone propionate is a corticosteroid that binds to glucocorticoid receptors in the cytoplasm, translocates to the nucleus, and suppresses inflammatory gene transcription to reduce airway inflammation. Used for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD), Allergic rhinitis.
At a glance
| Generic name | Fluticasone Propionate (FP) |
|---|---|
| Also known as | No other names applicable |
| Sponsor | Dey |
| Drug class | Inhaled corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory / Pulmonology |
| Phase | FDA-approved |
Mechanism of action
As a potent inhaled corticosteroid, fluticasone propionate exerts its anti-inflammatory effects by binding to intracellular glucocorticoid receptors and modulating the expression of pro-inflammatory cytokines, chemokines, and adhesion molecules. This reduces mucus production, airway edema, and eosinophil infiltration. The drug is designed for topical delivery to the lungs to minimize systemic exposure while maximizing local therapeutic benefit.
Approved indications
- Asthma maintenance therapy
- Chronic obstructive pulmonary disease (COPD)
- Allergic rhinitis
Common side effects
- Tremor
- Headache
- Palpitations
- Nervousness
- Throat irritation
- Oral candidiasis
Key clinical trials
- A Trial to Evaluate EP-104GI in Adults With Eosinophilic Esophagitis (EoE). (PHASE1, PHASE2)
- A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma (PHASE3)
- Pharmacokinetic Profile and Safety of Fluticasone Propionate and Albuterol Sulfate in Combination When Compared to Fluticasone Propionate Multidose Dry Powder Inhaler (Fp MDPI) in Children Aged 4 to 11 Years Old (PHASE1)
- Airway Microbiota Based Treatment of Asthma in Preschool Children (PHASE4)
- Effects of Mometasone Furoate Dry Powder Inhaler, Fluticasone Propionate, and Montelukast on Bone Mineral Density in Asthmatics (Study P03418) (PHASE4)
- A Proof of Concept Study to Evaluate the Dose Response for the Systemic Benefit Risk Ratio of Inhaled Fluticasone Propionate in Chronic Obstructive Pulmonary Disease (PHASE4)
- The Causal Relation of Nasal Nitric Oxide Levels to the Severity of Chronic Rhinosinusitis and Its Inflammatory Phenotype (NA)
- Bioequivalence Study to Assess Systemic Exposure of FP and SAL FDC From Different DPIs (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fluticasone Propionate (FP) CI brief — competitive landscape report
- Fluticasone Propionate (FP) updates RSS · CI watch RSS
- Dey portfolio CI